posted
Ingen Enters Hospital and Therapy Markets With Expected Revenue Increase CEO Live Radio Broadcast Talks About These New Markets
Press Release Source: Ingen Technologies, Inc. On 4:15 pm EST, Friday November 20, 2009 Buzz up! 0 Print Companies:Ingen Technologies, Inc.
YUCAIPA, Calif., Nov. 20, 2009 (GLOBE NEWSWIRE) -- Ingen Technologies, Inc. (Pink Sheets:IGNT - News), a leading global Medical Device Manufacturer focused on the $4B Respiratory market with their Oxyview products for the growing aging population and emerging markets for Home (DME), Hospital and Aviation industries, announced today that the company is now marketing direct to the hospital and therapy respiratory markets. Ingen's CEO, Scott Sand, will discuss these new markets this coming Tuesday, November 24, 2009 at 11:34AM eastern standard time on The Money Channel's American Scene Radio with host Steve Crowley.
Related Quotes Symbol Price Change IGNT.PK 0.00 0.00
{"s" : "ignt.pk","k" : "c10,l10,p20,t10","o" : "","j" : ""} According to the most recent report published in June 2009 and made available on the Global Market Research Information Network, respiratory market revenues are high currently, with good potential for sales increases. As the patient population grows and respiratory diseases become more prevalent, the market has the potential for continued growth in many countries and therapeutic areas. There is a great demand for products that provide therapeutic and commercial benefits in this demanding and competitive market. The developing markets of Asia, Latin America and Europe will drive sales increases in particular.
The company is introducing its new Oxyview Nasal Cannula at the America Association of Respiratory Care (AARC) on December 5 - 7, 2009 as an exhibitor. There are 47,000 members of AARC who are hospital based clinicians, therapists and managers, and a large majority will be attending this annual meeting in San Antonio, Texas.
"Our focus has been home health care markets and this is going very smoothly with an increase in sales from home oxygen patients and oxygen providers. Our GSA application is expected to be approved in the near future, and with the growing hospital markets in respiratory care, the Oxyview Nasal Cannula will be an attractive device for hospital nursing as it has shown to save time and provide additional assurance of oxygen flow. Our near final ISO Certification expected in late December 2009 and our recent issue/publication of our patent in the People's Republic of China is in alignment with the future demand for our Oxyview Nasal Cannula in various export countries according to the most recent studies," stated Scott Sand, Chief Executive Officer and Chairman of the Board.
About Ingen: Ingen is an established medical device manufacturer with an emerging new medical product line for the respiratory market worth an estimated $4 Billion in the US, and $8 billion globally. The company introduced Oxyview into the respiratory market in late 2007 after securing US and Foreign Patents and successful licensing with the Food & Drug Administration, and has commenced domestic and global distribution with manufacture representative organizations and OEM partners. In 2009, the company introduced the new Oxyview Nasal Cannula for adult, children and infants, with issued patents in China and the USA, and pending patents in Japan, Canada and European Communities expected to be issued in 2010. In addition to selling its respiratory products within the global medical industry, the company is selling the same products within other industries that include aviation, automotive, emergency response, military and government transportation. The company holds a Device Manufacturing License with the State of California, Department of Public Health, Food and Drug Branch as it manufacturers all of its respiratory products in the United States. There are 32 million US patients with Chronic Obstructive Pulmonary Disease (COPD), and 600 million patients worldwide. Ingen Technologies is now the largest manufacturer of in-line gravity-independent oxygen flow meters.
Safe Harbor for Forward-Looking Statements: This news release includes forward-looking statements. While these statements are made to convey to the public the company's progress, business opportunities and growth prospects, readers are cautioned that such forward-looking statements represent management's opinion. Whereas management believes such representations to be true and accurate based on information and data available to the company at this time, actual results may differ materially from those described. The company's operations and business prospects are always subject to risk and uncertainties. Important factors that may cause actual results to differ are and will be set forth in the company's periodic filings with the U.S. Securities and Exchange Commission.
IP: Logged |
IGNT - Tradeing with high volume today!!! This is one to watch!!! RSI LINE approaching Bullish - Mac D running even
This leading medical device manufacture that is focused on the $4B respiratory market with their oxyview products for the growing ageing population & emerging markets for home.
A growing elderly popuulation increase in home oxygen therapy & surgeries, & an increase in chronic obstructive pulmonary dieseases in the USA has resulted in an increase of buyers for Ingen’s new Oxyview Nasal Cannula. Now provides models for adults, pediatrics & infants.
The Oxyview Nasal Cannula is the only oxygen cannula in the world with a flow meter built-in that provides extremely accurate flow readings.
IP: Logged |
posted
Photo Release -- Ingen at Home Plate Ready to Catch Sales of $10M in 2010 and $50M in 2012 Press Release Source: Ingen Technologies, Inc. On 5:36 pm EST, Monday November 23, 2009 Buzz up! 0 Print Companies:Ingen Technologies, Inc.
YUCAIPA, Calif., Nov. 23, 2009 (GLOBE NEWSWIRE) -- Ingen Technologies, Inc. (Pink Sheets:IGNT - News), a leading global Medical Device Manufacturer focused on the $4B Respiratory market with their Oxyview products for the growing aging population and emerging markets for Home (DME), Hospital and Aviation industries announced today that expected sales projections for 2010 and 2012 are on target.
Related Quotes Symbol Price Change IGNT.PK 0.0029 +0.0001
The company's ISO Certification in December 2009 also allows Ingen to begin shipping product of its new Oxyview Nasal Cannula and Oxyview to China, Europe, Australia, Japan and Canada. Export sales will represent the majority of our $10M in 2010, and by 2012 reach $50M.The company's ISO consultant, Emergo Consulting Group, is assisting with both the ISO and CE Mark, as well as introducing these products to their distribution partners for export in these countries.
In addition to ISO Certification, the company expects to have in place its GSA contract with various government sectors including VA Hospitals and the Department of Defense in 3-4 weeks.
"Emergo Consulting Group will provide us with the outcome of the MEDICA exhibit in Germany, and this will be provided in a news release later this week. The Oxyview Nasal Cannula has received serious interest from institutional buyers, oxygen providers and suppliers, and patients. Sales have been made to all of these sectors in the past 2 months, and interest continues to grow," stated Scott R. Sand, Chief Executive Officer and Chairman of the Board.
About Ingen: Ingen is an established medical device manufacturer with an emerging new medical product line for the respiratory market worth an estimated $4 Billion in the U.S., and $8 billion globally. The company introduced Oxyview into the respiratory market in late 2007 after securing U.S. and Foreign Patents and successful licensing with the Food & Drug Administration, and has commenced domestic and global distribution with manufacture representative organizations, and OEM partners. In 2009, the company introduced the new Oxyview Nasal Cannula for adults, children and infants. In addition to selling its respiratory products within the global medical industry, the company is selling the same products within other industries that include aviation, automotive, emergency response, military and government transportation. The company holds a Device Manufacturing License with the State of California, Department of Public Health, Food and Drug Branch as it manufacturers all of its respiratory products in the United States. There are 32 million U.S. patients with Chronic Obstructive Pulmonary Disease (COPD), and 600 million patients worldwide. Ingen Technologies is now the largest manufacturer of in-line gravity-independent oxygen flow meters.
Safe Harbor for Forward-Looking Statements: This news release includes forward-looking statements. While these statements are made to convey to the public the company's progress, business opportunities and growth prospects, readers are cautioned that such forward-looking statements represent management's opinion. Whereas management believes such representations to be true and accurate based on information and data available to the company at this time, actual results may differ materially from those described. The company's operations and business prospects are always subject to risk and uncertainties. Important factors that may cause actual results to differ are and will be set forth in the company's periodic filings with the U.S. Securities and Exchange Commission.
IP: Logged |
posted
Thanks for the new news on IGNT! Interest in this company continues to be progressive. IMO, once the GSA contract is solidified there will be no stopping this company!!!
IP: Logged |
posted
Photo Release -- Ingen Launches the New Oxyview Pulse Oximeter Another Giant Leap for Ingen
.Companies:Ingen Technologies, Inc..Press Release Source: Ingen Technologies, Inc. On Wednesday January 6, 2010, 1:36 pm
YUCAIPA, Calif., Jan. 6, 2010 (GLOBE NEWSWIRE) -- Ingen Technologies, Inc. (Pink Sheets:IGNT - News), a leading global Medical Device Manufacturer for the Oxyview Nasal Cannula, focused on the $4B Respiratory market for the growing aging population and emerging markets for Home (DME), Hospital and Aviation industries, announced today the introduction of the new Oxyview Pulse Oximeter.
The Oxyview Pulse Oximeter is a very important and common device to check patient blood-oxygen saturation (SpO2) level and pulse rate. As a small, compact, simple, reliable and durable physiological monitoring device, the Oxyview Pulse Oximeter greatly enhances patient care, and fits both Adult and Pediatric patients. This small & lightweight design has a measurement range of 70% - 100%, and requires two AAA batteries. It has a Resolution of 1% with a measurement accuracy of 70% - 100%: +/- 3%. Some of the features include a dual color OLED display, display SpO2, PR, Pulse bar and Plethysmogram, 6 display modes, low power consumption, automatic power off, battery-low indicator, and an adjustable brightness feature.
This dynamic new product is the most sophisticated and cost competitive pulse oximeter in the market today. The company is selling the new device for $88.00, and when patients purchase the Oxyview Nasal Cannula they will earn points and receive the new Oxyview Pulse Oximeter at a discount. The market for this device includes the home oxygen patient market and the hospital markets.
"This new device will greatly enhance our revenues with expected sales of $1M in 2010, and increased sales with GSA contracts and our new distribution. The new Oxyview Pulse Oximeter has features that no other oximeter can offer, and the price is far less than that of any other Oximeter in its class," stated Scott R. Sand, Chief Executive Officer and Chairman of the Board.
IP: Logged |
posted
Ingen Introduces Oxyview Products at ATS Effective Advertising and Product Branding Scheduled for 2010
.Companies:Ingen Technologies, Inc..Press Release Source: Ingen Technologies, Inc. On Thursday January 14, 2010, 8:15 am
YUCAIPA, Calif., Jan. 14, 2010 (GLOBE NEWSWIRE) -- Ingen Technologies, Inc. (Pink Sheets:IGNT - News), a leading manufacturer of respiratory medical devices, recently announced the introduction of their Oxyview product line at the 2010 ATS International Conference on May 14-19, 2010 in New Orleans, Louisiana.
The American Thoracic Society (ATS) is committed to disseminating the latest advances, nationally and internationally, in the fields of lung disease, sleep disorders and critical care medicine. The annual International Conference has become the premier, international forum for physicians and scientists who work in pulmonary, critical care, and sleep medicine.
The company will reach 13,000 pulmonologists through the advertising in Medco Forum's ATS issue that is scheduled to be released on May 1, 2010. Medco Forum will also host the Oxyview advertising on their website.
The company now advertises in several major publications, inclusive of COPD Digest, Today's Senior Magazine and Medco Forum.
Throughout 2009, Ingen showcased their newest medical respiratory equipment at several conventions, including the MEDICA convention in Germany and the American Association of Respiratory Care (AARC) in San Antonio, Texas. These showings captured the attention of many distributors who were interested in Oxyview, taking Ingen a step closer to achieving international distribution and a growing presence in the hospital and therapy markets.
As the number of respiratory diseases continue to increase, so too does the number of patients requiring oxygen support. That's why Ingen expects to see more demand for the Oxyview Nasal Cannula and the Oxyview Pulse Oximeter in 2010 and the coming years. The company expects to acquire more distributors in the United States and the developing markets of Asia, Canada, Australia and Europe.
Ingen is an established medical device manufacturer with an emerging new medical product line for the respiratory market worth an estimated $4 Billion in the U.S., and $8 billion globally. The company introduced Oxyview into the respiratory market in late 2007 after securing US and Foreign Patents and a successful registration with the Food & Drug Administration. The company has domestic and global distribution with manufacture representative organizations, and OEM partners. In 2009 the Oxyview Nasal Cannula was introduced as the world's first oxygen cannula with an in-line pneumatic oxygen flow meter. In 2010 the company introduced the Oxyview Pulse Oximeter. The Oxyview product line is available to the home care markets, commercial medical markets, aviation, automotive, and government sources. The company is licensed with the Department of Health and Human Services, and manufactures its products in the State of California. With approximately 32 million U.S. patients with Chronic Obstructive Pulmonary Disease (COPD), and 600 million patients worldwide, Ingen Technologies is now the largest manufacturer of in-line gravity-independent oxygen flow meters.
IP: Logged |
posted
IGNT Off to a slow start this morning. Stock is bearish right now but with this news that came out on the stock this morning I expect this stock to bounce back this afternoon and tmw. I also think today the stock will push through .25 and .26 today and see more apprecation tmw. I personally am playing this as a swing trade. Remember to do ur own research and this is strictly my opinion
IP: Logged |
posted
2010 Looks to be a Big Year for Ingen Technologies The Company Expects More Distributors, in the U.S. and Abroad, to Pick Up Oxyview
.Companies:Ingen Technologies, Inc..Press Release Source: Ingen Technologies, Inc. On Thursday January 14, 2010, 2:00 pm
YUCAIPA, Calif., Jan. 14, 2010 (GLOBE NEWSWIRE) -- Ingen Technologies, Inc. (Pink Sheets:IGNT - News), a leading manufacturer of respiratory medical devices, recently announced that they will engage Medical Strategies International (MSI) to increase sales of the Oxyview product line through GPO contracts.
MSI specializes in helping companies increase sales through Group Purchasing Organizations (GPOs), Integrated Delivery Networks (IDNs), and Equipment Planners. Medical Strategies International (MSI) is a strategic business-consulting firm focused on the Medical industry. MSI's Executive Team is highly trained healthcare professionals with over 70 years experience in the Sales, Marketing, Government and Corporate Account Management of medical products and services. Our goal is to assist companies that manufacture or distribute products and services to the Hospital/Physician market and help them increase sales through the extremely important arena of Healthcare Group Purchasing Organizations and Integrated Health Delivery Networks.
In the United States, a healthcare group purchasing organization (or GPO) is an entity that is created to leverage the purchasing power of a group of hospitals to obtain discounts from vendors based on the collective buying power of the GPO members. Group purchasing is used in many industries to purchase raw materials and supplies, but it is common practice in the health care industry.
The Oxyview Nasal Cannula has garnered a lot of attention at several conventions throughout the world. This showing captured the attention of many distributors who are interested in this new medical technology, opening the doors to the possibility that Oxyview will become available worldwide to patients outside of the United States by March of 2010. Ingen recently unveiled its latest in medical respiratory equipment; the new Oxyview Pulse Oximeter.
In 2010, the adult nasal cannula manufacturer plans to aggressively market its medical devices to hospitals. But Ingen's bold plans for growth don't end here. The company also hopes to work with distributors to make the Oxyview product line available worldwide beginning in March-2010. Recently, at the MEDICA convention in Germany, Ingen's showcase of Oxyview earned the company attention from multiple distributors that were on hand for the event.
"We look forward to working with Ken Kuiper of Medical Strategies International. Our plan is to capture the VA Hospital market with our expected GSA approval, and capture the commercial hospital market through GPO contracts. The Oxyview Nasal Cannula and the Oxyview Pulse Oximeter will be a great improvement to oxygen therapy in the hospital setting," stated Scott R. Sand, Chief Executive Officer and Chairman of the Board.
IP: Logged |
posted
Ignt a strong buy today. News came out this morning. Keep this stock on your radar list. I am currently going to take a position with a few other investors on this company. A good time to buy this stock while the price is low. I expect this stock to break through the 20 day ma of .0021 and bounce hold at the 50 day ma of .0026. good luck to you all!!
IP: Logged |
posted
I LISTENED TO THE INTERVIEW OVER MY LUNCH BREAK http://www.moneychannel.tv/archive.php LISTEN TO FRIDAY IF YOU WANT. THE HOST OF THE SHOW STEVE CROWLEY RECOMENDED IGNT AS A BUY AND HOLD.SO MUCH FOR GETTING OUT QUICK. HAVE TO THINK ABOUT THIS NOW.
IP: Logged |
posted
YUCAIPA, Calif., Jan 21, 2010 (GlobeNewswire via COMTEX) -- Ingen Technologies, Inc. (Pink Sheets:IGNT), a leading manufacturer of respiratory medical devices, recently announced that it has received several bulk purchases from various hospitals around the country. Columbia Memorial Hospital submitted a bulk purchase order for the new Oxyview Pulse Oximeter, and this is a strong indication of increased sales for 2010. On January 14, 2010, the company received a purchase order from the Oregon based Columbia Memorial Hospital for the new Oxyview Pulse Oximeter. The Company has signed a contract with MediGroup to develop various GPO proposals and will move forward this quarter to align strategic national GPO contracts with the hospital industry.
"We look forward to working with Andy Klearman, President of MediGroup. This group was brought to the table by Charles Vorwaller, one of our Board of Directors. We expect to sell all of our products to hospitals, and MediGroup has the expertise to develop this distribution channel for the company," stated Scott R. Sand, Chief Executive Officer and Chairman of the Board.
IP: Logged |
posted
Photo Release -- Ingen Targets Lung Specialists With Oxyview Products COPD Foundation Will Include Oxyview Ad in Their New Publication for Next Month
.Companies:Ingen Technologies, Inc..Press Release Source: Ingen Technologies, Inc. On Wednesday January 27, 2010, 8:15 am
YUCAIPA, Calif., Jan. 27, 2010 (GLOBE NEWSWIRE) -- Ingen Technologies, Inc. (Pink Sheets:IGNT - News), a leading manufacturer of respiratory medical devices, recently announced today that it has approved an insertion order with COPD Foundation's new magazine that targets 20,000-30,000 lung specialists that includes physicians, respiratory therapists, nurse practitioners, and other lung specialists.
The company already has a 12 month contract with the COPD Foundation's COPD Digest magazine that is distributed once each quarter to over 200,000 subscribers. The new magazine will be released next month and includes articles and submissions by a variety of academics and clinicians, and will be focused on articles of interest to those treating patients with pulmonary diseases. These lung specialists represent 15,000,000 patients with COPD and various lung disorders in the USA.
"We look forward to working with Mitch Ruttner of the COPD Foundation and supporting the efficacy of their program. Mr. Ruttner has also been very proactive with our Oxyview product line, as we continue to direct a strong focus in the commercial hospital markets to sell our products. We continue to see an increase with hospital orders for bulk purchases, and this is an indicator that our Oxyview products are being recognized by hospitals. We are very appreciative for all of the support Ingen continues to receive from credible sources and shareholders," stated Scott R. Sand, Chief Executive Officer and Chairman of the Board.
posted
Ignt had news today.Stock is trading well today. Myself and other smart money have taken a position in this stock today. We should see more price aprecation today and this week. The new magazine insert should bring more focus towards the company and the great products they produce. This company has a bright future and we can all profit from it. Remember this is my opinion and to do your own dd. Hope all your stocks are in the green!!!
IP: Logged |
posted
Ingen Takes Final Steps Towards Increased Export Sales ISO Auditor Approves Stage-I for Ingen
.Companies:Ingen Technologies, Inc..Press Release Source: Ingen Technologies, Inc. On Tuesday February 9, 2010, 8:15 am
YUCAIPA, Calif., Feb. 9, 2010 (GLOBE NEWSWIRE) -- Ingen Technologies, Inc. (Pink Sheets:IGNT - News), a leading manufacturer of respiratory medical devices, recently announced today that the company was granted approval of the Stage-I audit conducted by BSI America, Inc. on February 5, 2010.
On February 5, 2010 the company was audited by Mr. Brian Nguyen, one of the certified auditors with BSI America, Inc. According to Mr. Nguyen, Ingen's management system documentation meets the requirements of the ISO 13485:2003, the MDD 93/42/EEC Annex V (M5), and the CMDR. The internal audits and management review processes are being planned and performed. Based on the objective evidences noted from the areas assessed during this Stage-I audit, it is recommended that Ingen proceed to the final Stage-II audit. There were no outstanding non-conformities to review from previous assessments. No new non-conformities were identified during the assessment.
Ingen Technologies is strongly committed to the success of this company and continues driving forward in a direction that is within the best interest of its shareholders. The company has pending back-orders for export sales to China, Japan, Canada, Europe and Australia. Ingen has seen an increase in the value with its intellectual property, research & development, new medical product lines, inventory and other assets, while revenues show a steady incline. ISO Certification is expected to result in a large revenue jump of the company's respiratory product lines.
IP: Logged |
UBBFriend: Email this page to someone!
Printer-friendly view of this topic
